MedTrace Logo

A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

NCT00169156 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-03-13

No results posted yet for this study

Summary

To evaluate the efficacy and the safety of a front-line treatment combining CHOP regimen and rituximab in patients aged 60 to 80 years with previously untreated AIL.

Conditions

  • Untreated T-cell Angioimmunoblastic Lymphoma

Interventions

DRUG

Rituximab

375 mg/m2 D1

DRUG

Prednisone

40 mg/m2 D1 to D5

DRUG

Doxorubicine

50 mg/m2 D1

DRUG

Cyclophosphamide

750 mg/m2 D1

DRUG

Vincristine

1,4 mg/m2 D1

Sponsors & Collaborators

Principal Investigators

  • Corinne Haioun, MD · Hôpital Henri Mondor, Créteil, France

  • Bertrand Joly, MD · C.H. Sud Francilien, Corbeil-Essonnes, France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-12-31
Completion
2012-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169156 on ClinicalTrials.gov